Navigation Links
Einstein researcher receives American Cancer Society Medal of Honor
Date:11/9/2010

November 5, 2010 (BRONX, NY) Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

Insights into how normal body cells support tumor growth have led the way to a new wave of research and the development of therapeutics specifically targeting the support cells in the body that can aid in tumor development. Dr. Pollard's research has found that when macrophages are removed from the tumor microenvironment, the risk of cancer progressing to malignancy is reduced and its spread from the primary tumor site to distant sites lessens.

"I think that one of the major components of the therapeutic arsenal as we go forward will be to combine chemo-therapeutic drugs with drugs that target macrophages so that they can no longer support the tumor's ability to be malignant," said Dr. Pollard. "Further it gives another opportunity for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It gives us another prong in the attack on cancer."

Dr. Pollard is deputy director of the Albert Einstein Cancer Center, director of the Center for Study of Reproductive Biology and Women's Health and the Louis Goldstein Swan Chair in Women's Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women's health at Einstein and Montefiore Medical Center.

This award from the American Cancer Society, the nation's leading voluntary health organization and largest non-governmental investor in cancer research, represents the Society's highest honor in recognition of outstanding contributions to fighting cancer.

The award was presented at the American Cancer Society's annual meeting in Atlanta, GA. In addition to Dr. Pollard, the ACS recognized Joseph Fraumeni, M.D., M.Sc., for Cancer Control, and Patricia Ganz, M.D., for Clinical Research.

This is the second ACS Medal of Honor awarded to a researcher at the Albert Einstein Cancer Center. Susan Band Horwitz, Ph.D., received the Medal of Honor in 2008 for Clinical Research.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein receives $30 million to study protein form and function
2. Einstein designated an NIH Center of Excellence for aging research
3. Einstein receives $4 million to test HPV microbicide
4. Einstein researcher awarded prestigious cancer research grant
5. Einstein-Montefiore research tackles childhood obesity in the Bronx
6. Einstein researchers discover 2 new ways to kill TB
7. Einstein receives high-risk/high-reward cancer research funding
8. Einstein to develop anti-HIV drug delivery system
9. Einstein scientists move closer to a safer anthrax vaccine
10. Einstein researchers devise a fast and sensitive way to detect ricin
11. NIH funds research center for womens reproductive health at Einstein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
(Date:11/30/2016)... 2016   Merck , ein führendes ... einer Reihe von Vereinbarungen mit Evotec AG ... Screeningleistungen für Mercks Palette genetischer Reagenzien wie ... diese Bibliotheken in Kombination mit Evotecs Expertise ... zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
Breaking Biology Technology: